McKesson (MCK) Peer Comparison
$893.39
$2.88
(0.32%)
As on 28-Aug-2026 16:11EDT
Market cap
$97,790 Mln
Revenue (TTM)
$410,983 Mln
P/E Ratio
22.9
P/B Ratio
5
Div. Yield
0.4 %
Edit
| McKesson (MCK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
97,790 | 1,109,683 | 644,335 | 462,684 | 367,584 |
Revenue ($ Mln) |
410,983 | 79,666 | 97,929 | 64,386 | 66,400 |
Net Profit ($ Mln) |
4,592.00 | 26,709.50 | 21,037.00 | 6,314.00 | 3,173.00 |
Net Margin (%) |
1.12 | 33.53 | 21.48 | 9.81 | 4.78 |
RoE (%) |
-- | 88.42 | 25.27 | -- | 6.72 |
Price to Earnings |
22.89 | 42.93 | 31.75 | 75.24 | 122.12 |
Price-To-Book |
5.04 | 33.69 | 7.75 | 50.46 | 8.95 |
Income Statement ($ Mln)
| McKesson (MCK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
403,430.00 | 65,179.00 | 94,193.00 | 61,160.00 | 64,926.00 |
|
Cost of Revenue
|
388,880.00 | 10,564.00 | 25,635.00 | 18,204.00 | 18,195.00 |
|
Gross Profit
|
14,550.00 | 54,615.00 | 68,558.00 | 42,956.00 | 46,731.00 |
|
Operating Expenses
|
8,096.00 | 24,919.00 | 42,962.00 | 22,865.00 | 23,245.00 |
|
Operating Profit (EBIT)
|
6,454.00 | 29,696.00 | 25,596.00 | 20,091.00 | 23,486.00 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
6,201.00 | 25,729.90 | 32,581.00 | 6,597.00 | 21,067.00 |
|
Provision for Tax
|
1,102.00 | 5,091.60 | 5,777.00 | 2,364.00 | 2,804.00 |
|
Profit after Tax (Net Income)
|
4,762.00 | 20,638.30 | 26,804.00 | 4,226.00 | 18,254.00 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
3,295.00 | 20,640.00 | 26,804.00 | -- | 18,254.00 |
Liabilities ($ Mln)
| McKesson (MCK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-2,172.00 | 26,535.00 | 81,544.00 | -3,228.00 | 52,606.00 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
16,140.00 | 50,713.00 | 63,540.00 | 93,899.00 | 55,877.00 |
|
Current Liabilities
|
67,017.00 | 35,228.00 | 54,126.00 | 43,289.00 | 28,327.00 |
|
Total Liabilities
|
82,323.00 | 112,476.00 | 199,210.00 | 133,960.00 | 136,866.00 |
Assets ($ Mln)
| McKesson (MCK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
25,113.00 | 56,847.00 | 143,586.00 | 104,898.00 | 93,350.00 |
|
Current Assets
|
57,210.00 | 55,629.00 | 55,624.00 | 29,062.00 | 43,516.00 |
|
Total Assets
|
82,323.00 | 112,476.00 | 199,210.00 | 133,960.00 | 136,866.00 |
|
Total Debt*
|
8,614.00 | 42,503.00 | 47,933.00 | 69,068.00 | 50,534.00 |
|
Net Current Assets
|
-9,807.00 | 20,401.00 | 1,498.00 | -14,227.00 | 15,189.00 |
Cashflow ($ Mln)
| McKesson (MCK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
6,155.00 | 16,813.00 | 24,530.00 | 19,030.00 | 16,472.00 |
|
Cash Flow from Investing Activities
|
-3,432.00 | -10,972.00 | -23,588.00 | -6,643.00 | -13,741.00 |
|
Cash from Financing Activities
|
-4,631.00 | -2,213.00 | -5,539.00 | -12,724.00 | -1,922.00 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| McKesson (MCK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
78.46 | 35.32 | 22.56 | 6.17 | 19.45 |
|
ROE (%)
|
-246.35 | 101.35 | 35.03 | 6,214.71 | 36.91 |
|
ROA (%)
|
6.05 | 21.59 | 14.13 | 3.14 | 14.37 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
1.18 | 31.66 | 28.46 | 6.91 | 28.12 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| McKesson (MCK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.12 | 0.45 | 0.06 | 0.09 | 0.01 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
44.52 | 94.88 | 90.56 | -1.22 | 6.64 |
|
EPS Growth (%)
|
0.48 | 0.96 | 0.90 | -0.01 | 0.09 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| McKesson (MCK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
22.30 | 46.76 | 18.83 | 95.92 | 14.35 |
|
Price / Book Value
|
-48.89 | 36.37 | 6.19 | -125.57 | 4.98 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
15.44 | 35.81 | 12.97 | 26.61 | 10.54 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| McKesson (MCK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-3.97 | 1.60 | 0.59 | -21.40 | 0.96 |
|
Short term debt to equity ratio
|
-0.72 | 0.06 | 0.10 | -2.71 | 0.05 |
|
Current Ratio
|
0.85 | 1.58 | 1.03 | 0.67 | 1.54 |
|
Quick Ratio
|
0.49 | 1.19 | 0.77 | 0.56 | 1.30 |
|
Interest Coverage
|
26.11 | 33.16 | 34.55 | 3.28 | 16.52 |
Operating Efficiency Ratios
| McKesson (MCK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Merck & Company Inc (MRK) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
6.94 | 30.92 | 18.24 | 20.58 | 19.53 |
|
Asset Turnover
|
5.12 | 0.68 | 0.50 | 0.45 | 0.51 |
|
Receivable days
|
24.28 | 93.67 | 70.00 | 70.20 | 64.57 |
|
Inventory Days
|
22.17 | 368.80 | 189.75 | 91.61 | 128.14 |
|
Payable days
|
54.15 | 148.80 | 158.88 | 65.58 | 85.14 |
|
Cash Conversion Cycle
|
-7.70 | 313.66 | 100.87 | 96.23 | 107.57 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
